Amylyx Pharmaceuticals | 10-Q: FY2025 Q2 Revenue: USD 0

Revenue: As of FY2025 Q2, the actual value is USD 0.

EPS: As of FY2025 Q2, the actual value is USD -0.46, missing the estimate of USD -0.45.

EBIT: As of FY2025 Q2, the actual value is USD -41.44 M.

Segment Revenue

• Product Revenue, Net: No revenue generated from product sales for the three and six months ended June 30, 2025, due to the discontinuation of RELYVRIO®/ALBRIOZA™.

Operational Metrics

• Net Loss: For the three months ended June 30, 2025, net loss was - $41.4 million, compared to - $72.7 million for the same period in 2024, representing a 43% decrease. For the six months ended June 30, 2025, net loss was - $77.4 million, compared to - $191.5 million for the same period in 2024, representing a 60% decrease.
• Research and Development Expenses: Increased to $27.2 million for the three months ended June 30, 2025, from $23.3 million for the same period in 2024, primarily due to increased expenses related to the Phase 3 LUCIDITY clinical trial for avexitide. For the six months ended June 30, 2025, expenses decreased to $49.3 million from $60.0 million in 2024.
• Selling, General and Administrative Expenses: Decreased to $15.6 million for the three months ended June 30, 2025, from $21.6 million for the same period in 2024. For the six months ended June 30, 2025, expenses decreased to $31.3 million from $79.4 million in 2024.

Cash Flow

• Net Cash Used in Operating Activities: For the six months ended June 30, 2025, net cash used was - $65.1 million, compared to - $67.1 million for the same period in 2024.
• Net Cash Used in Investing Activities: For the six months ended June 30, 2025, net cash used was - $20.7 million, compared to - $28.1 million for the same period in 2024.
• Net Cash Provided by Financing Activities: For the six months ended June 30, 2025, net cash provided was $65.6 million, compared to $0.2 million for the same period in 2024.

Unique Metrics

• Stock-Based Compensation Expense: Total stock-based compensation expense was $7.4 million for the three months ended June 30, 2025, compared to $9.6 million for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company is focused on advancing its pipeline, including the pivotal Phase 3 LUCIDITY clinical trial for avexitide in PBH, and the Phase 2b/3 ORION trial for AMX0035 in PSP. Completion of recruitment for LUCIDITY is expected in 2025, with topline data anticipated in the first half of 2026.
• Non-Core Business: The company announced a collaboration with Gubra A/S for the development of a potential novel long-acting GLP-1 receptor antagonist.